Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106696

Radioimmunassay for measurement of triiodothyronine in human serum

Inder J. Chopra, David H. Solomon, and Gildon N. Beall

Department of Medicine, Harbor General Hospital, Torrance, California 90509

University of California Los Angeles School of Medicine, Los Angeles, California 90024

Find articles by Chopra, I. in: PubMed | Google Scholar

Department of Medicine, Harbor General Hospital, Torrance, California 90509

University of California Los Angeles School of Medicine, Los Angeles, California 90024

Find articles by Solomon, D. in: PubMed | Google Scholar

Department of Medicine, Harbor General Hospital, Torrance, California 90509

University of California Los Angeles School of Medicine, Los Angeles, California 90024

Find articles by Beall, G. in: PubMed | Google Scholar

Published October 1, 1971 - More info

Published in Volume 50, Issue 10 on October 1, 1971
J Clin Invest. 1971;50(10):2033–2041. https://doi.org/10.1172/JCI106696.
© 1971 The American Society for Clinical Investigation
Published October 1, 1971 - Version history
View PDF
Abstract

A convenient, specific, precise, and reproducible radioimmunoassay system for measurement of triiodothyronine (T3) in human serum has been developed. The procedure compares the ability of standards and unknowns to compete with radioactive T3 for binding sites on a T3-binding antiserum produced in rabbits by immunization with human thyroglobulin. The assay is set up in the presence of 250 ng thyroxine (T4) in all tubes, to mobilize T3 from its binding with the thyronine-binding globulin (TBG), and athyreotic sheep serum in standards to correct for the TBG in the unknowns. The method regularly detected 0.4 ng T3, which would correspond to a T3 concentration of 100 ng/100 ml when 400 μl of serum is analyzed. The mean recovery of unlabeled T3 added to normal serum pools was 106%. Serial dilution of hyperthyroid sera containing high concentrations of T3 with athyreotic sheep serum yielded expected values.

The serum T3 concentration in 80% of 31 euthyroid normal subjects was less than 100 ng/100 ml (range < 100-170 ng/100 ml); it was greater than 170 ng/100 ml in 89% of 27 sera of hyperthyroid patients with untreated Graves' disease (range < 100-1300, mean 519 in 25 sera with detectable T3). The concentration of serum T3 fell, frequently to undetectable levels, during treatment of hyperthyroid patients with antithyroid drugs. The serum T3 concentration in four hypothyroid patients was less than 100 ng/100 ml.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2033
page 2033
icon of scanned page 2034
page 2034
icon of scanned page 2035
page 2035
icon of scanned page 2036
page 2036
icon of scanned page 2037
page 2037
icon of scanned page 2038
page 2038
icon of scanned page 2039
page 2039
icon of scanned page 2040
page 2040
icon of scanned page 2041
page 2041
Version history
  • Version 1 (October 1, 1971): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts